Nicole Dressel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Dressel has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Gerbaulet
Institute for Immunology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany
17 shared publications - Axel Roers
Institute for Immunology, Heidelberg University Hospital, Heidelberg, Germany
17 shared publications - Clara Marie Munz
Institute For Regeneration and Repair Centre For Reproductive Health Centre For Inflammation Research University of Edinburgh Edinburgh UK
17 shared publications - Andreas Dahl
DRESDEN-concept Genome Center (DcGC), Center for Molecular and Cellular Bioengineering (CMCB) Technology Platform, TUD Dresden University of Technology, 01062 Dresden, Germany
16 shared publications - Angela Rösen-Wolff
Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden
16 shared publications - Anja Loff
Institute for Immunology, Faculty of Medicine, TU Dresden, Dresden, Germany
16 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis
Supplementary Figures S1-8 and corresponding figure legends
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis
Supplementary Figures S1-8 and corresponding figure legends
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis
List of antibodies used in the study
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis
List of antibodies used in the study
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
List of antibodies used in the study
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
List of antibodies used in the study
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Genome damage is a main driver of malignant transformation, but it also induces aberrant inflammation via the cGAS/STING DNA sensing pathway. Activation of cGAS/STING can trigger cell death and senescence, thereby potentially eliminating genome-damaged cells and preventing against malignant transformation. Here, we report that defective ribonucleotide excision repair (RER) in the hematopoietic system caused genome instability with concomitant activation of the cGAS/STING axis and compromised hematopoietic stem cell function, ultimately resulting in leukemogenesis. Additional inactivation of cGAS, STING, or type I IFN signaling, however, had no detectable effect on blood cell generation and leukemia development in RER-deficient hematopoietic cells. In wild-type mice, hematopoiesis under steady-state conditions and in response to genome damage was not affected by loss of cGAS. Together, this data challenges a role of the cGAS/STING pathway in protecting the hematopoietic system against DNA damage and leukemic transformation.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Genome damage is a main driver of malignant transformation, but it also induces aberrant inflammation via the cGAS/STING DNA sensing pathway. Activation of cGAS/STING can trigger cell death and senescence, thereby potentially eliminating genome-damaged cells and preventing against malignant transformation. Here, we report that defective ribonucleotide excision repair (RER) in the hematopoietic system caused genome instability with concomitant activation of the cGAS/STING axis and compromised hematopoietic stem cell function, ultimately resulting in leukemogenesis. Additional inactivation of cGAS, STING, or type I IFN signaling, however, had no detectable effect on blood cell generation and leukemia development in RER-deficient hematopoietic cells. In wild-type mice, hematopoiesis under steady-state conditions and in response to genome damage was not affected by loss of cGAS. Together, this data challenges a role of the cGAS/STING pathway in protecting the hematopoietic system against DNA damage and leukemic transformation.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S3-5 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Supplementary Tables S3-5 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S3-5 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Supplementary Tables S3-5 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Table S2 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Table S2 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Supplementary Figures S1-8 and corresponding figure legends
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Supplementary Figures S1-8 and corresponding figure legends
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S3-5 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Supplementary Tables S3-5 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S3-5 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis
Supplementary Tables S3-5 from Activation of the cGAS/STING axis in genome-damaged hematopoietic cells does not impact blood cell formation or leukemogenesis